MYRX Share Price

Open 0.00 Change Price %
High 0.00 1 Day 0.00 0.00
Low 0.00 1 Week 0.00 0.00
Close 0.04 1 Month 0.01 33.33
Volume 8 1 Year -0.04 -50.00
52 Week High 0.10
52 Week Low 0.00
MYRX Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.01
Support 1 0.04
Support 2 0.04
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
DSTI 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Myrexis, Inc (NASDAQ: MYRX)

MYRX Technical Analysis 4
As on 5th Dec 2016 MYRX Share Price closed @ 0.04 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.07 & Sell for SHORT-TERM with Stoploss of 0.05 we also expect STOCK to react on Following IMPORTANT LEVELS.
MYRX Target for December
1st Target up-side 0.06
2nd Target up-side 0.08
3rd Target up-side 0.1
1st Target down-side N/A
2nd Target down-side -0.02
3rd Target down-side -0.04
MYRX Other Details
Segment EQ
Market Capital 64093332.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.myrexis.com
MYRX Address
MYRX
630 Fifth Avenue
Suite 2260
New York, NY 10020
United States
Phone: 801-214-7800
Interactive Technical Analysis Chart Myrexis, Inc ( MYRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Myrexis, Inc
MYRX Business Profile
Myrexis Inc, is a biopharmaceutical company that has generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. The Company retains all rights to all of its drug candidates and programs across all geographic markets and therapeutic indications. In February 2012, the Company suspended development activities in oncology programs and are actively pursuing business development opportunities with respect to them. In February 2012, the Company suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a range of strategic alternatives to enhance shareholder value.